[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"pancreatic-cancer-stage-iii\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:pancreatic-cancer-stage-iii":24},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,45,83],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":28,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100393729","the-role-of-microrna-in-the-diagnosis-prognosis-and-response-to-treatment-in-pancreatic-cancer-100393729",false,"NCT04406831","The Role of MicroRNA in the Diagnosis, Prognosis and Response to Treatment in Pancreatic Cancer","Inclusion Criteria:\n\n* Have biopsy proven adenocarcinoma of the pancreas\n* Have initially inoperable disease, classified as either locally advanced or metastatic disease\n\n  * Recurrent disease after a Whipple procedure is allowed\n  * Patients who are able to undergo resection after neoadjuvant therapy will continue to be followed after resection\n* Have radiographically measurable disease\n* Have an ECOG performance status of 2 or less\n* Be willing to contribute the required information and specimens\n* Provide written signed consent to participate\n\nExclusion Criteria:\n\n* Having received prior anti-cancer treatments for metastatic pancreatic cancer\n* Concurrently receiving systemic therapy for another cancer except androgen deprivation therapy for stable\u002Fcontrolled prostate cancer\n* Presence of other active cancer except for: adequately treated local basal or squamous cell carcinoma of the skin, cervical carcinoma in situ, superficial bladder cancer, asymptomatic prostate cancer without known metastatic disease and with no requirement for therapy or requiring only hormonal therapy and with normal prostate-specific antigen for \\>1 year prior to start of trial. Other adequately treated Stage 1 or 2 cancer currently in complete remission, or any other cancer that has been in complete remission for \\> 5 years is allowable",true,"ALL","18 Years",{"count":19,"type":20},200,"ESTIMATED","OBSERVATIONAL","Aberrant miRNA production has been linked to a wide range of human cancers and shown to play important roles in their genesis and growth. These miRNA can be detected in the blood and tumors of patients with cancer. The investigators hypothesize that the detection of certain miRNAs present in the blood\u002Fserum of patients with pancreatic cancer may be important to the early diagnosis of the disease. Furthermore, the investigators hypothesize that miRNA detection in PC patients will yield prognostic information and help predict the response to treatment.",[24,25,26,27],"Pancreatic Cancer Stage III","Pancreatic Cancer Stage IV","Pancreatic Ductal Adenocarcinoma","Pancreatic Neoplasms",[29,30,31],"Pancreas","Cancer","Biomarker","RECRUITING","2026-04-06",{"date":35,"type":36},"2026-04-13","ACTUAL",{"date":38,"type":36},"2015-04",{"date":40,"type":20},"2030-04",{"name":42,"class":43},"Nuvance Health","OTHER",1,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":51,"eligibilityCriteria":52,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":53,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":55,"conditions":56,"keywords":67,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":73,"lastUpdatePostDateStruct":74,"startDateStruct":76,"completionDateStruct":78,"leadSponsor":80,"locationsCount":82},"100545979","pancreatic-cancer-detection-consortium-100545979","NCT06388967","Pancreatic Cancer Detection Consortium","Early Detection of Pancreatic Cancer: Prospective Study","PCDC","Inclusion Criteria:\n\n* Histological diagnosis of pancreatic ductal adenocarcinoma, stages I-IV (TNM classification, 8th edition)\n* Received standard diagnostic and staging procedures as per local guidelines, and at least one sample was drawn before receiving any curative-intent treatment.\n* Imaging- or endoscopy-based proof of lack of pancreatic ductal adenocarcinoma at the time of sampling (Non-disease controls)\n\nExclusion Criteria:\n\n* Lack of written informed consent.",{"count":54,"type":20},2000,"This study aims to prospective validate an exosome-based miRNA signature for noninvasive and early detection of pancreatic ductal adenocarcinoma.",[57,58,59,26,27,60,61,62,63,64,24,65,66],"Pancreatic Cancer","Pancreatic Carcinoma","Pancreatic Adenocarcinoma","Pancreatic Cancer Stage I","Pancreatic Cancer Stage","Pancreatic Cancer Resectable","Pancreatic Cancer Stage 0","Pancreatic Cancer Stage II","Pancreatic Cancer, Adult","Pancreatic Cancer Non-resectable",[68,69,70,71,72],"Micro RNA","Exosome","Cell free","Early detection","Screening","2025-12-17",{"date":75,"type":36},"2025-12-19",{"date":77,"type":36},"2023-03-15",{"date":79,"type":20},"2026-06-18",{"name":81,"class":43},"City of Hope Medical Center",11,{"id":84,"slug":85,"hasResults":11,"nctId":86,"briefTitle":87,"officialTitle":88,"acronym":4,"eligibilityCriteria":89,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":90,"enrollmentInfo":91,"targetDuration":4,"studyType":93,"phases":94,"briefSummary":96,"conditions":97,"keywords":101,"overallStatus":107,"whyStopped":4,"lastUpdateSubmitDate":108,"lastUpdatePostDateStruct":109,"startDateStruct":111,"completionDateStruct":113,"leadSponsor":115,"locationsCount":44},"100482458","phase-2-neoadjuvantadjuvant-sintilimab-nab-paclitaxel-and-gemcitabine-for-resectableborderline-resectable-pancreatic-cancer-100482458","NCT05562297","Neoadjuvant\u002FAdjuvant Sintilimab, Nab-paclitaxel, and Gemcitabine for Resectable\u002FBorderline Resectable Pancreatic Cancer","A Phase II Study to Evaluate the Safety and Efficacy of Sintilimab Combined With Nab-paclitaxel and Gemcitabine for Neoadjuvant and Adjuvant Therapy of Patients With Resectable and Borderline Resectable Pancreatic Cancer","Inclusion Criteria:\n\n* Signed informed content obtained prior to treatment\n* Age ≥ 18 years and ≤ 75 years\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1\n* Patients must have imaging evaluations to confirm that their pancreatic adenocarcinoma is resectable and borderline resectable. Patients must have histologically confirmed pancreatic adenocarcinoma, too.\n* Therapy-naïve for their pancreatic cancer. Patients should receive no anti-tumor treatment, including systemic chemotherapy, interventional chemotherapy, high-energy focused ultrasound, radiotherapy, immunotherapy, molecular targeted therapy, and anti-tumor Chinese medicine therapy.\n* No serious dysfunction in blood system, heart, lung function, or autoimmune system (refer to the respective diagnostic criteria)\n* White blood cell (WBC) ≥ 3 × 109\u002FL; Absolute neutrophil count (ANC) ≥ 1.5 × 109\u002FL; Platelets (PLT) ≥ 100 × 109\u002FL; Hemoglobin (Hgb) ≥ 90 g\u002FL\n* Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase \\[SGOT\\]\u002F alanine aminotransferase (ALT) (serum glutamic pyruvate transaminase \\[SGPT\\]) ≤ 2.5 × institutional upper limit of normal (ULN); Total bilirubin (TBIL) ≤ ULN; Creatinine (CRE) ≤ 1.5 × ULN\n* Prothrombin time (PT) and international normalized ratio (INR) ≤ 1.5 × ULN\n* Able to comply with research visit plans and other protocol requirements.\n\nExclusion Criteria:\n\n* The diameter of the resectable tumor is ≤ 2 cm in imaging evaluation\n* Associated with other malignant tumors\n* Patients receiving anti-tumor treatment before neoadjuvant therapy, including systemic chemotherapy, interventional chemotherapy, high-energy focused ultrasound, radiotherapy, immunotherapy, molecular targeted therapy, and anti-tumor Chinese medicine therapy\n* Use of any other investigational agents\n* Patients with uncontrolled intercurrent illness including, but not limited to ongoing or active infection, internal hemorrhage, pancreatic leakage, bile leakage, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness\u002Fsocial situations that would limit compliance with study requirements\n* Pregnant or nursing women\n* History of allergic reactions attributed to compounds of similar chemical or biological composition to nab-paclitaxel, gemcitabine, or sintilimab\n* Patients who are using and need to use warfarin for a long period\n* Patients who are unwilling or unable to comply with study procedures\n* Patients who are expected to be out of the observation period for 14 days or more during the treatment","75 Years",{"count":92,"type":20},50,"INTERVENTIONAL",[95],"PHASE2","The purpose of this research is to investigate the activity and safety of the combination of gemcitabine plus nab-paclitaxel and sintilimab as neoadjuvant therapy in treating patients with resectable and borderline resectable pancreatic cancer.\n\nThe drugs involved in this study are:\n\n* Sintilimab\n* Nab-paclitaxel\n* Gemcitabine",[98,99,100,24],"Pancreatic Cancer, Stage IB","Pancreatic Cancer, Stage IIA","Pancreatic Cancer, Stage IIB",[57,26,102,103,104,105,106],"Sintilimab","Nab-paclitaxel","Gemcitabine","Neoadjuvant Therapy","Adjuvant Therapy","NOT_YET_RECRUITING","2025-01-19",{"date":110,"type":36},"2025-01-22",{"date":112,"type":20},"2025-03-20",{"date":114,"type":20},"2028-10-01",{"name":116,"class":43},"Shanghai Zhongshan Hospital"]